Delcath Systems Inc

DCTH · Moat type: UNBESTIMMT

MoatScore

0/10

Fair Value

3 USD

Margin of Safety

-392.7 %

Rating

MEIDEN

Delcath Systems develops and markets the HEPZATO KIT System (Hepatic Artery Infusion), a specialized oncological treatment procedure for regional chemotherapy in hepatic metastases, which generates revenue through the sale of single-use kits and associated melphalan chemotherapeutic agents.

View full analysis →

🔒 Detailed AI analysis, peer comparison, capital allocation, crisis resilience & PDF report for Pro members.

Not investment advice. Analyses are research, not a recommendation. Valuations may be erroneous or incomplete. © MoatScan.ai — proprietary methodology.